Compare Dr. Reddys with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs NATCO PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB NATCO PHARMA DR. REDDYS LAB/
NATCO PHARMA
 
P/E (TTM) x 22.2 15.8 140.1% View Chart
P/BV x 3.3 3.1 106.8% View Chart
Dividend Yield % 0.7 1.4 49.7%  

Financials

 DR. REDDYS LAB   NATCO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
NATCO PHARMA
Mar-18
DR. REDDYS LAB/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,8751,080 266.2%   
Low Rs1,888671 281.2%   
Sales per share (Unadj.) Rs930.2592.1 157.1%  
Earnings per share (Unadj.) Rs117.4188.4 62.3%  
Cash flow per share (Unadj.) Rs185.8206.3 90.0%  
Dividends per share (Unadj.) Rs20.008.25 242.4%  
Dividend yield (eoy) %0.80.9 89.1%  
Book value per share (Unadj.) Rs844.4833.6 101.3%  
Shares outstanding (eoy) m166.0736.90 450.1%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.61.5 173.1%   
Avg P/E ratio x20.34.6 436.4%  
P/CF ratio (eoy) x12.84.2 302.1%  
Price / Book Value ratio x2.81.1 268.5%  
Dividend payout %17.04.4 389.0%   
Avg Mkt Cap Rs m395,49632,311 1,224.0%   
No. of employees `00022.04.8 454.7%   
Total wages/salary Rs m33,5623,256 1,030.8%   
Avg. sales/employee Rs Th7,032.84,522.5 155.5%   
Avg. wages/employee Rs Th1,527.9674.0 226.7%   
Avg. net profit/employee Rs Th887.71,439.0 61.7%   
INCOME DATA
Net Sales Rs m154,48221,848 707.1%  
Other income Rs m3,375404 835.4%   
Total revenues Rs m157,85722,252 709.4%   
Gross profit Rs m31,7829,284 342.3%  
Depreciation Rs m11,348662 1,714.2%   
Interest Rs m889154 577.3%   
Profit before tax Rs m22,9208,872 258.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8581,920 200.9%   
Profit after tax Rs m19,5006,952 280.5%  
Gross profit margin %20.642.5 48.4%  
Effective tax rate %16.821.6 77.8%   
Net profit margin %12.631.8 39.7%  
BALANCE SHEET DATA
Current assets Rs m111,10121,307 521.4%   
Current liabilities Rs m58,9735,920 996.2%   
Net working cap to sales %33.770.4 47.9%  
Current ratio x1.93.6 52.3%  
Inventory Days Days7973 108.3%  
Debtors Days Days94107 88.4%  
Net fixed assets Rs m101,24514,986 675.6%   
Share capital Rs m830369 224.9%   
"Free" reserves Rs m139,40630,353 459.3%   
Net worth Rs m140,23630,760 455.9%   
Long term debt Rs m22,0000-   
Total assets Rs m224,65637,151 604.7%  
Interest coverage x26.858.6 45.7%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.6 116.9%   
Return on assets %9.119.1 47.4%  
Return on equity %13.922.6 61.5%  
Return on capital %14.929.3 50.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67310,322 859.1%   
Fx outflow Rs m19,1042,978 641.4%   
Net fx Rs m69,5697,343 947.4%   
CASH FLOW
From Operations Rs m28,7044,636 619.2%  
From Investments Rs m-7,727-11,155 69.3%  
From Financial Activity Rs m-21,3266,509 -327.6%  
Net Cashflow Rs m-314-18 1,744.4%  

Share Holding

Indian Promoters % 25.5 52.0 49.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 5.4 7.8 68.9%  
FIIs % 35.3 16.6 212.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 26.0 58.8%  
Shareholders   75,885 25,395 298.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   FRESENIUS KABI ONCO.  SUN PHARMA  PFIZER  TTK HEALTHCARE  SHASUN PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling, Key Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

India share markets ended their day deep in the red yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 22, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - SHASUN PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS